Barclays maintains BridgeBio Pharma at Overweight
Barclays maintained its Overweight rating on BridgeBio Pharma, according to Benzinga’s ratings-action roundup.
Story updates
01:45:46 PM UTC
SquawkNews
BridgeBio Pharma Price Target Cut to $156.00/Share From $157.00 by Barclays